Merck wins speedy FDA review for 15-valent pneumococcal vaccine

In phase 2 studies, V114 has been shown to match Pfizer’s Prevnar-13 on the 13 serotypes covered by Pfizer’s vaccine in adults, with the added bonus of tackling ... If approved, Merck’s V114 will be a close competitor of Pfizer's Prevnar-13,

Roche’s flu pill Xofluza gains EU approval

The proportion of household members aged 12 years and above who developed influenza was 1.3% in the Xofluza treatment group compared to 13.2% in the placebo arm.

Amgen aims for first KRAS inhibitor approval in the US

In NSCLC, KRAS G12C is the most common KRAS mutation, with around 13% of patients with NSCLC in the US carrying this particular mutation. ... Data from the phase 1 trial found that seven (53%) of 13 experienced NSCLC patients with the KRAS G12C mutation

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

Among 32 patients enrolled in the 13-year, long-term LTF-303 study, 64% of patients treated in the phase 1/2 portion and 90% in the phase 2 portion achieved

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]